Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Twelve projects, including 10 domestic projects and two foreign-invested ones with a total investment exceeding 1 billion, ...

Chinese researchers use AI to identify HG9-91-01, a potential neuroprotective treatment for glaucoma. The molecule shows ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Taiwan-based GlycoNex, a biotech company focused on the development of glycan-directed cancer immunotherapies, has announced a licensing agreement for its denosumab biosimilar, SPD8.

As you improve your ability to say ‘no’ and focus on what only the IR team can do, you release time: time for personal growth ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Europe Viscosupplementation MarketThe Europe viscosupplementation market is poised for significant growth, with its valuation rising from USD 4.91 billion in 2023 to an estimated USD 12.03 billion by ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...